Acrivon Therapeutics, Inc. (ACRV)

Acrivon Therapeutics' stock has experienced volatility due to clinical trial updates and earnings reports. In January 2026, the stock plummeted following mixed results from cancer treatment trials for ACR-368, despite the announcement of ACR-6840 as a preclinical development candidate. A clinical update notice in December 2025 also coincided with a negative stock price reaction. In November 2025, the company reported a net loss of $18.2 million and cash of $134.4 million, leading to a stock decrease. October 2025 saw preclinical data shared for ACR-2316, resulting in a slight negative price reaction. Overall, the stock declined by 57.64% between January 2, 2025, and December 31, 2025, and had decreased by 33.20% over the 10 days preceding January 13, 2026.

Information regarding demand seasonality for Acrivon Therapeutics' products and services is not readily available. As a clinical-stage biopharmaceutical company, its activities primarily involve drug development and clinical trials, rather than the sale of commercialized products that would exhibit demand seasonality.

Acrivon Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing precision oncology medicines, operating within the Biotechnology industry. Acrivon uses its AP3 platform to identify patients likely to respond to its drug candidates. Its pipeline includes ACR-368 (prexasertib), a CHK1 and CHK2 inhibitor in a Phase 2 trial; ACR-2316, a preclinical dual WEE1 and PKMYT1 inhibitor; and ACR-6840, a potential first-in-class oral CDK11 inhibitor with an IND submission planned for Q4 2026.

Acrivon Therapeutics is headquartered in Watertown, Massachusetts, and operates out of Greater Boston and Medicon Valley in Southern Scandinavia. The company collaborates with cancer centers and translational science groups across North America and Europe.

Acrivon Therapeutics' brand reputation has been influenced by its clinical trial outcomes. Mixed results for ACR-368 in January 2026 led to a stock price drop, potentially impacting the company's reputation. Positive initial clinical data from a Phase 2 study of ACR-368 and progress with its AP3 platform earlier in 2024 positively contributed to its reputation.

Acrivon Therapeutics has a mixed ownership structure. Institutional shareholders hold approximately 34.78% to 55.40% of the stock, with Ra Capital Management, L.P. being a significant holder. Insiders own approximately 44.25% to 46.81% of the stock, with Chione Ltd as the largest individual shareholder. Retail investors hold around 0.00% to 16.27% of the stock.